V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330011221 | 330003454 | null | null | Curative (C) | 2015-06-11 | 2015-06-29 | Cisplatin + Radiotherapy | N | Y | 330003353 | CISPLATIN + RT |
| 330011222 | 330003455 | 1.57 | 85.9 | Curative (C) | 2014-04-13 | 2014-04-19 | Cisplatin + Radiotherapy | N | Y | 330003354 | CISPLATIN + RT |
| 330011223 | 330003458 | null | 42.7 | Curative (C) | 2016-05-26 | 2016-07-16 | Cisplatin 100 + RT(H&N) 1 day | N | null | 330003376 | CISPLATIN + RT |
| 330011224 | 330003460 | null | 73 | Curative (C) | 2014-11-06 | 2014-12-16 | NB Rel CCLG guidelines Irin & Temoz | N | N | 330003386 | NOT MATCHED |
| 330011225 | 330003463 | null | 25.5 | Palliative (P) | 2016-07-29 | 2016-08-02 | CNS LGG2004 03 vinc + carbo | null | null | 330003394 | NOT MATCHED |
| 330011226 | 330003465 | 0 | 15.3 | Palliative (P) | 2016-07-21 | 2016-12-26 | CNS LGG 2004 03 cons vinc + carbo | N | N | 330003396 | NOT MATCHED |
| 330011227 | 330010269 | 0 | null | Palliative (P) | 2017-09-21 | 2017-10-09 | null | null | N | 330003402 | NOT MATCHED |
| 330011228 | 330003471 | null | 10.3 | Neo-adjuvant (N) | 2014-07-16 | 2014-07-31 | NB HRNBL-1 COJEC Ind COURSE C | Y | N | 330003438 | NOT MATCHED |
| 330011229 | 330003473 | 1.81 | 73.6 | Curative (C) | 2013-09-02 | 2013-12-12 | CISPLATIN + RT | N | N | 330003451 | CISPLATIN + RT |
| 330011231 | 330003479 | 1.71 | 85.5 | 2 | 2017-02-21 | 2017-02-21 | Cisplatin 100 + RT(H&N) 1 day | 02 | Y | 330003481 | CISPLATIN + RT |
| 330011232 | 330003480 | 0 | null | Palliative (P) | 2014-06-26 | 2014-07-17 | NB HRNBL-1 TVD | null | N | 330003485 | NOT MATCHED |
| 330011233 | 330003482 | 1.57 | 22 | Adjuvant (A) | 2014-01-22 | 2014-09-29 | WT SIOP 2002 01 post op Carbo, Etop | Y | N | 330003495 | NOT MATCHED |
| 330011234 | 330003484 | null | 12.5 | Curative (C) | 2014-01-16 | 2014-07-18 | CNS GCT II Non Germin - HDose PEI | 02 | N | 330003503 | NOT MATCHED |
| 330011235 | 330003486 | 0 | 68.1 | Palliative (P) | 2014-08-01 | 2014-08-02 | CNS LGG 2004 03 con vinc +cisplatin | N | N | 330003509 | NOT MATCHED |
| 330011236 | 330011603 | 0 | 14.9 | Disease modification (D) | 2015-08-12 | 2015-08-03 | ETOPOSIDE + IFOSFAMIDE + METHOTREXATE | 2 | null | 330003518 | NOT MATCHED |
| 330011237 | 330007868 | null | 26 | Adjuvant (A) | 2013-07-11 | 2014-01-29 | EW Rel rEECur Topotecan/Cyclophosphamide | 02 | N | 330003528 | NOT MATCHED |
| 330011238 | 330003494 | 1.81 | 86.05 | Palliative (P) | 2018-07-24 | 2018-08-17 | EW Rel rEECur Gemcitabine/Docetaxel | N | null | 330003535 | NOT MATCHED |
| 330011239 | 330003495 | null | 28.3 | Curative (C) | 2013-05-08 | 2014-03-11 | NB HRNBL-1 COJEC Ind COURSE B | N | N | 330003536 | NOT MATCHED |
| 330011240 | 330003498 | 1.51 | null | Curative (C) | 2017-01-20 | 2017-03-18 | Cisplatin 100 + RT(H&N) 1 day | 02 | N | 330003565 | CISPLATIN + RT |
| 330011241 | 330003500 | 0 | null | Disease modification (D) | 2017-02-13 | 2017-02-13 | NB 13 cis-RA (Isotretinoin) | N | null | 330003568 | NOT MATCHED |
| 330011242 | 330003502 | 0.86 | 4.7 | Curative (C) | 2014-08-24 | 2014-08-30 | NB HRNBL-1 ch14.18/CHO only (trial) | 02 | N | 330003578 | NOT MATCHED |
| 330011243 | 330003518 | 0 | 79.7 | Disease modification (D) | 2014-10-12 | 2015-08-05 | NB HRNBL-1 ch14.18/CHO(trial) +IL-2 | Y | N | 330003643 | NOT MATCHED |
| 330011244 | 330003520 | 1.72 | 97.2 | null | 2018-04-18 | 2018-04-24 | CISPLATIN + RT | N | Y | 330003651 | CISPLATIN + RT |
| 330011245 | 330003520 | null | null | Curative (C) | 2017-12-17 | 2018-06-07 | Cisplatin 100 + RT(H&N) 1 day | N | Y | 330003651 | CISPLATIN + RT |
| 330011246 | 330003523 | 1.66 | 88.8 | Adjuvant (A) | 2016-06-05 | 2016-06-23 | Cisplatin + Radiotherapy | N | Y | 330003677 | CISPLATIN + RT |
| 330011247 | 330003527 | 0 | 20.4 | Disease modification (D) | 2014-05-14 | 2014-05-20 | NB HRNBL-1 ch14.18/CHO only (trial) | Y | N | 330003708 | NOT MATCHED |
| 330011249 | 330003530 | null | 13.2 | Curative (C) | 2013-04-13 | 2013-04-23 | NB HRNBL-1 COJEC Ind COURSE B | Y | null | 330003721 | NOT MATCHED |
| 330011250 | 330003532 | 0 | 40 | Adjuvant (A) | 2014-11-30 | 2014-12-05 | CNS ATRT VCA Vinc/Dactino/Cyclophos + GCSF | null | N | 330003734 | NOT MATCHED |
| 330011251 | 330003536 | 1.57 | 54 | Curative (C) | null | 2017-05-12 | DOXORUBICIN | null | null | 330003743 | DOXORUBICIN |
| 330011253 | 330007897 | 1.81 | 35.8 | Curative (C) | null | 2016-11-11 | OST Euramos 1 Closed Trial - A | null | null | 330004198 | DOXORUBICIN |
| 330011254 | 330007898 | 1.72 | null | Adjuvant (A) | 2014-02-01 | 2014-02-02 | R2W trial | null | null | 330004563 | TRIAL |
| 330011255 | 330003544 | 1.46 | 56 | Palliative (P) | 2017-12-17 | 2017-12-17 | Trial Unspecified | null | null | 330004796 | TRIAL |
| 330011256 | 330003547 | 1.58 | 108 | Curative (C) | 2015-05-09 | 2015-05-23 | CNS Medbl HR Cyclo+Vinc | 2 | Y | 330004842 | TRIAL |
| 330011257 | 330003550 | 1.87 | 74.7 | Curative (C) | 2015-03-12 | 2015-03-25 | MIFAMURTIDE | Y | Y | 330004954 | MIFAMURTIDE |
| 330011258 | 330003552 | 0 | 35.8 | Curative (C) | 2017-02-20 | 2017-06-26 | Trial Unspecified | Y | N | 330004963 | TRIAL |
| 330011259 | 330003553 | 1.69 | 61.1 | Curative (C) | null | 2017-02-01 | MIFAMURTIDE | N | null | 330004971 | MIFAMURTIDE |
| 330011260 | 330003555 | 1.83 | 22 | Neo-adjuvant (N) | null | 2018-02-26 | METHOTREXATE | N | null | 330004985 | METHOTREXATE |
| 330011261 | 330003558 | 1.6 | 71 | Adjuvant (A) | 2016-10-07 | 2016-10-14 | OST Mifamurtide | Y | Y | 330005004 | MIFAMURTIDE |
| 330011262 | 330010301 | 0 | 59.5 | Curative (C) | 2015-12-02 | 2016-08-13 | EW EuroEwing 2012 Arm B IE | N | N | 330005070 | TRIAL |
| 330011263 | 330003564 | 1.68 | 86 | Neo-adjuvant (N) | 2014-07-21 | 2014-07-26 | Trial Unspecified | null | null | 330005102 | TRIAL |
| 330011264 | 330003570 | 1.61 | 47.7 | Neo-adjuvant (N) | 2017-05-23 | 2017-06-20 | CNS Medbl HR Cyclo+Vinc | 2 | N | 330005138 | TRIAL |
| 330011265 | 330007921 | null | 18 | Neo-adjuvant (N) | 2013-08-14 | 2014-01-28 | Trial Unspecified | null | null | 330005195 | TRIAL |
| 330011266 | 330003579 | 1.59 | null | Adjuvant (A) | null | 2014-08-26 | DOXORUBICIN | null | null | 330005201 | DOXORUBICIN |
| 330011267 | 330003581 | 1.58 | 51.6 | Adjuvant (A) | 2018-08-14 | 2018-09-10 | Cisplatin 7 day | N | null | 330005203 | CISPLATIN |
| 330011268 | 330003585 | null | 84.4 | Adjuvant (A) | 2013-02-17 | 2013-09-08 | MIFAMURTIDE | N | N | 330005221 | MIFAMURTIDE |
| 330011269 | 330003590 | 1.73 | 104.6 | Neo-adjuvant (N) | null | 2018-04-25 | Methotrexate + Folinic acid | Y | null | 330005262 | METHOTREXATE |
| 330011270 | 330007930 | 1.69 | 79.2 | Palliative (P) | 2014-10-29 | 2015-08-03 | Trial Unspecified | null | null | 330005264 | TRIAL |
| 330011271 | 330003600 | 1.58 | null | Palliative (P) | null | 2017-12-01 | OST Euramos 1 Closed Trial - A | Y | null | 330005294 | DOXORUBICIN |
| 330011272 | 330003601 | 1.84 | 63.4 | Adjuvant (A) | null | 2014-07-29 | METHOTREXATE | N | null | 330005305 | METHOTREXATE |
| 330011273 | 330007935 | 1.54 | null | Curative (C) | 2018-11-05 | 2018-11-13 | Trial Unspecified | N | N | 330005315 | TRIAL |